A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Phase 2 Completed
20 enrolled
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Phase 1/2 Completed
47 enrolled 36 charts
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Phase 1 Completed
12 enrolled 12 charts
Molecular-Guided Therapy for Childhood Cancer
Phase NA Completed
186 enrolled 12 charts
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
18 enrolled 12 charts
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
4 enrolled 12 charts
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Phase 2 Completed
5 enrolled
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Phase 1 Completed
24 enrolled
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Phase 1 Completed
15 enrolled
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase 2 Completed
78 enrolled 11 charts
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
AflacST1501
Phase 1 Completed
53 enrolled
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase 1/2 Completed
140 enrolled 23 charts
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Phase 2 Completed
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Phase 1 Completed
25 enrolled
Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody
Completed
76 enrolled
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed
1,720 enrolled
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
Completed
482 enrolled
Aflac ST0901
Phase 1 Completed
18 enrolled
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 2 Completed
118 enrolled 24 charts
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Phase 1 Completed
89 enrolled
AflacST1402
Phase 1 Completed
13 enrolled
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase 1/2 Completed
107 enrolled 42 charts
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Phase 1 Completed
18 enrolled
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
Phase 1 Completed
50 enrolled
Informed Consent in Pediatric Cancer Trials
Completed
1 enrolled
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
Phase 1 Completed
19 enrolled
High-dose ICE With Amifostine
Phase 2 Completed
24 enrolled
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Phase 1 Completed
6 enrolled
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase 2 Completed
22 enrolled 6 charts
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Phase 2 Completed
100 enrolled
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 2 Completed
116 enrolled 8 charts
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Completed
17 enrolled
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Phase 2 Completed
120 enrolled
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
Phase 1 Completed
28 enrolled
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Phase 1 Completed
16 enrolled
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Phase 3 Completed
130 enrolled 9 charts
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Phase 1 Completed
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
Phase 1 Completed
36 enrolled
Irinotecan in Treating Children With Refractory Solid Tumors
Phase 2 Completed
181 enrolled
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
95 enrolled
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Phase 1 Completed
70 enrolled